Zentalis Pharmaceuticals (ZNTL) Liabilities and Shareholders Equity (2019 - 2026)

Zentalis Pharmaceuticals' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $253.1 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 34.1% year-over-year to $253.1 million; the TTM figure through Mar 2026 stood at $1.2 billion (down 30.5% YoY), while the FY2025 annual figure was $289.0 million, down 32.85% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $253.1 million, down from $289.0 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $621.4 million in Q2 2023, with the low at $253.1 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $489.3 million (2023), against an average of $460.3 million.
• The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity jumped 99.98% in 2022, then tumbled 34.1% in 2026.
• Zentalis Pharmaceuticals' Liabilities and Shareholders Equity stood at $539.3 million in 2022, then grew by 2.3% to $551.7 million in 2023, then retreated by 22.0% to $430.3 million in 2024, then tumbled by 32.85% to $289.0 million in 2025, then retreated by 12.42% to $253.1 million in 2026.
• Business Quant data shows ZNTL's Liabilities and Shareholders Equity at $253.1 million in Q1 2026, $289.0 million in Q4 2025, and $327.2 million in Q3 2025.